Movember marches on and as we near the end, I wanted to share my personal progress and also that of our Thomson Reuters campaign.
As we grow our sometimes comedic “Mo’s” and smile in solidarity at our fellow participants, it is important to remember that at the heart of this initiative is a very important cause and some rather thought-provoking statistics.
In the United Kingdom: (more…)
A Florida appeals court has refused to overturn a $33 million award ($8 million in compensatory damages and $25 million in punitive damages) won by the widow of a deceased smoker against Lorillard Tobacco Co.
The 3rd District Court of Appeal rejected the cigarette maker’s arguments that the trial court committed errors that entitled it to a new trial and that the award amounts were excessive.
(Westlaw users: Click here for more stories from Westlaw Journal Tobacco Industry.) (more…)
Over the past decade, a multitude of targeted agents have been explored in the treatment of non-small-cell lung cancer (NSCLC) and there are now three classes of agents which have been implemented in clinical practice. The VEGF-directed therapy Avastin has shown landmark improvements in survival when added to cytotoxic therapy, while the EGFR-directed therapies Tarceva and Iressa have shown significant benefit and uncovered valuable information about the biology of the disease. Recently, inhibitors of ALK have also shown great promise in patients with the relevant gene translocation.
Download the latest Spotlight On: Non-Small-Cell Lung Cancer: A New Era in Personalized Care report based on the strategic data and insights from Thomson Reuters Cortellis for Competitive Intelligence.
This quarter’s Ones to Watch focuses on disease areas with the most promising drugs recently launched or receiving approval in: (more…)
As the US enters the fifth decade of its “war on cancer,” deaths continue to decline, according to an extensive report from the National Cancer Institute. But that doesn’t tell the whole story, as improvements reflect lifestyle changes like not smoking more than they do the billions of dollars spent to discover and implement advanced cancer treatments. Today’s graphic shows the average yearly change in incidence and mortality rates from a variety of cancers in men and women.
Lung cancer rates are rising among the 20 million residents of China’s capital, health officials say. Today’s graphic looks at air pollution in Chinese and other major cities and the health impact it has.
Click to enlarge
Join the discussion on our Facebook page or in the comment section below.
The festival’s second Thomson Reuters Knowledge Exchange event was titled “Cracking the Genetic Code,” and featured an excellent panel. Moderated by Chris Kibarian, president of our IP & Science business, the panel included Harvard professor John Quackenbush, Brian Fiske of the The Michael J. Fox Foundation, and Paul Rejto from Pfizer. The three panelists each brought a unique perspective to the discussion, and their varied expertise helped to turn complicated subject matter into something very easy to understand and enjoy.
The conversation started and revolved around the human genome, and the project to determine the sequence of chemical base pairs which make up DNA, as well as identifying the function of human genes. Professor Quackenbush almost poetically explained complicated scientific information so that it was easily comprehensible. He talked about the roadmap of the human genome and the new technologies that have contributed to the decreasing costs of identifying genes. He talked about a time in the very near future where the cost would become so low that we’d be able to generate huge amounts of data in an economically responsible manner. This data would then contribute to a better understanding about genetic factors contributing to risk of developing diseases and being able to develop more personalized care for serious illnesses. (more…)